自身免疫性肝炎及其治疗对健康效用的影响
基于英国自身免疫性肝炎(AIH)国家研究中的990例成人患者,使用EQ-5D-5L等工具评估健康相关生活质量与健康效用。AIH患者效用指数较英国人群常模显著受损,且皮质类固醇使用与生活质量受损显著相关,即使控制生化疾病活动状态后仍存在。
要点
- AIH患者EQ-5D-5L效用指数较英国人群常模显著受损。
- 皮质类固醇使用与生活质量受损显著相关,控制生化疾病活动后仍相关。
- 作者强调需要更好的无皮质类固醇治疗策略及未来新药试验。
核心结论
- AIH患者健康相关生活质量较一般人群受损,皮质类固醇使用与生活质量下降强相关,且不依赖缓解状态。
研究设计与样本
- 来自英国自身免疫性肝炎(UK-AIH)国家研究的大型现患病例队列,纳入990例临床诊断AIH的成人参与者,使用EQ-5D-5L等验证工具及临床数据表收集数据。
主要发现
- EQ-5D-5L效用指数显示AIH队列健康相关生活质量较人群常模显著受损。
- 在AIH队列内,皮质类固醇使用与健康相关生活质量受损显著相关,即使控制生化疾病活动状态后仍相关。
- EQ-5D-5L维度评分与英国人群常模及原发性胆汁性胆管炎(PBC)疾病对照队列进行了比较。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Patient reporting suggests that the physical and psychological effects of autoimmune hepatitis (AIH) can be substantial. However, health-related quality of life (HRQOL) in patients with AIH remains incompletely characterized, and health utility remains to be explored. Treatment for AIH often includes the use of corticosteroids, which are agents that can be associated with significant adverse effects. Here we explore the impact of AIH and its treatments on patient-reported HRQOL and health utility in a large cohort of prevalent cases from the United Kingdom Autoimmune Hepatitis (UK-AIH) national study. Data were collected from 990 adult participants with a clinical diagnosis of AIH using validated HRQOL tools including the European Quality-of-Life 5-Dimension 5-Level (EQ-5D-5L) and clinical data forms. The EQ-5D-5L dimension scores were compared with UK population norms and with a disease control cohort with primary biliary cholangitis (PBC). Within the AIH cohort, regression analysis was used to explore associations between HRQOL and demographic and clinical variables with a particular focus on the impact of AIH therapies including corticosteroid use. HRQOL, measured by the EQ-5D-5L utility index, is shown to be significantly impaired in our cohort of AIH patients compared with population norms. Within the AIH cohort, corticosteroid use was found to be significantly associated with impaired HRQOL, even when controlling for biochemical disease activity status. CONCLUSION: Our data show evidence of HRQOL impairment in a large cohort of AIH patients compared with the general population. Furthermore, corticosteroid use is strongly associated with decreased HRQOL, independent of remission status. This highlights the need for better corticosteroid-free therapy approaches and it emphasizes the need for future novel therapeutic trials in AIH. (Hepatology 2018; 00:000-000).
引用
- Wong LL, Fisher HF, Stocken DD, et al. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology. 2018. PMID: 29663477. doi:10.1002/hep.30031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。